메뉴 건너뛰기




Volumn 9, Issue 1, 2012, Pages 18-22

Molecular mechanisms contributing to resistance to tyrosine kinase-targeted therapy for non-small cell lung cancer

Author keywords

Carcinoma; Drug resistance; Mutation; Non small cell lung

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 3; ERLOTINIB; GEFITINIB; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN TYROSINE KINASE INHIBITOR; SCATTER FACTOR RECEPTOR; SOMATOMEDIN BINDING PROTEIN 3;

EID: 84876307790     PISSN: 20953941     EISSN: None     Source Type: Journal    
DOI: 10.3969/j.issn.2095-3941.2012.01.003     Document Type: Article
Times cited : (7)

References (36)
  • 2
    • 79551563284 scopus 로고    scopus 로고
    • International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma
    • Travis WD, Brambila E, Noguchi M, et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 2011; 6: 244-285.
    • (2011) J Thorac Oncol , vol.6 , pp. 244-285
    • Travis, W.D.1    Brambila, E.2    Noguchi, M.3
  • 3
    • 2342591455 scopus 로고    scopus 로고
    • The discovery of receptor tyrosine kinases: Targets for cancer therapy
    • Gschwind A, Fischer OM, Ullrich A. The discovery of receptor tyrosine kinases: Targets for cancer therapy. Nat Rev Cancer 2004; 4: 361-370.
    • (2004) Nat Rev Cancer , vol.4 , pp. 361-370
    • Gschwind, A.1    Fischer, O.M.2    Ullrich, A.3
  • 4
    • 33847323129 scopus 로고    scopus 로고
    • Epidermal growth factor receptor in lung cancer
    • Sharma SV, Bell DW, Settleman J, et al. Epidermal growth factor receptor in lung cancer. Nat Rev Cancer 2007; 7: 169-181.
    • (2007) Nat Rev Cancer , vol.7 , pp. 169-181
    • Sharma, S.V.1    Bell, D.W.2    Settleman, J.3
  • 5
    • 77958478674 scopus 로고    scopus 로고
    • Rational, biologically based treatment of EGFR-mutant non-small cell lung cancer
    • Pao W, Chmielecki J. Rational, biologically based treatment of EGFR-mutant non-small cell lung cancer. Nat Rev Cancer 2010; 10: 760-774.
    • (2010) Nat Rev Cancer , vol.10 , pp. 760-774
    • Pao, W.1    Chmielecki, J.2
  • 6
    • 77449147803 scopus 로고    scopus 로고
    • Advances in target therapy for lung cancer
    • Mitsudomi T. Advances in target therapy for lung cancer. Jpn J Clin Oncol 2010; 40: 101-106.
    • (2010) Jpn J Clin Oncol , vol.40 , pp. 101-106
    • Mitsudomi, T.1
  • 7
    • 73349096261 scopus 로고    scopus 로고
    • Resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer
    • Hammerman PS, Janne PA, Johnson BE. Resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res 2009; 15: 7502-7509.
    • (2009) Clin Cancer Res , vol.15 , pp. 7502-7509
    • Hammerman, P.S.1    Janne, P.A.2    Johnson, B.E.3
  • 8
    • 24744450387 scopus 로고    scopus 로고
    • Epidermal growth factor receptor mutations in patients with non-small cell lung cancer
    • Johnson BE, Janne PA. Epidermal growth factor receptor mutations in patients with non-small cell lung cancer. Cancer Res 2005; 65: 7525-7529.
    • (2005) Cancer Res , vol.65 , pp. 7525-7529
    • Johnson, B.E.1    Janne, P.A.2
  • 9
    • 67650378948 scopus 로고    scopus 로고
    • Combined survival analysis of prospective clinical trials of gefitinib for non-small cell lung cancer with EGFR mutations
    • Morita S, Okamoto I, Kobayashi K, et al. Combined survival analysis of prospective clinical trials of gefitinib for non-small cell lung cancer with EGFR mutations. Clin Cancer Res 2009; 15: 4493-4498.
    • (2009) Clin Cancer Res , vol.15 , pp. 4493-4498
    • Morita, S.1    Okamoto, I.2    Kobayashi, K.3
  • 10
    • 79958020132 scopus 로고    scopus 로고
    • EGFR-mutated lung cancer: A paradigm of molecular oncology
    • Zhang Z, Stiegler AL, Boggon TJ, et al. EGFR-mutated lung cancer: A paradigm of molecular oncology. Oncotarget 2010; 1: 497-514.
    • (2010) Oncotarget , vol.1 , pp. 497-514
    • Zhang, Z.1    Stiegler, A.L.2    Boggon, T.J.3
  • 11
    • 51049116207 scopus 로고    scopus 로고
    • Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response
    • Wu JY, Wu SG, Yang CH, et al. Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response. Clin Cancer Res 2008; 14: 4877-4882.
    • (2008) Clin Cancer Res , vol.14 , pp. 4877-4882
    • Wu, J.Y.1    Wu, S.G.2    Yang, C.H.3
  • 12
    • 68949201629 scopus 로고    scopus 로고
    • Activating and resistance mutations of EGFR in nonsmallcell lung cancer: Role in clinical response to EGFR tyrosine kinase inhibitors
    • S24-S31
    • Gazdar AF. Activating and resistance mutations of EGFR in nonsmallcell lung cancer: Role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene 2009; 28: S24-S31.
    • (2009) Oncogene , vol.28
    • Gazdar, A.F.1
  • 13
    • 78751535304 scopus 로고    scopus 로고
    • Prognostic and predictive implications of EGFR mutations, EGFR copy number and KRAS mutations in advanced stage lung adenocarcinoma
    • Bonanno L, Schiavon M, Nardo G, et al. Prognostic and predictive implications of EGFR mutations, EGFR copy number and KRAS mutations in advanced stage lung adenocarcinoma. Anticancer Res 2010; 30: 5121-5128.
    • (2010) Anticancer Res , vol.30 , pp. 5121-5128
    • Bonanno, L.1    Schiavon, M.2    Nardo, G.3
  • 14
    • 15744372810 scopus 로고    scopus 로고
    • KRAS Mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib
    • e17
    • Pao W, Wang TY, Riely GJ, et al. KRAS Mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2005; 2: e17.
    • (2005) PLoS Med , vol.2
    • Pao, W.1    Wang, T.Y.2    Riely, G.J.3
  • 15
    • 33745888913 scopus 로고    scopus 로고
    • PTEN function in normal and neoplastic growth
    • Chow LML, Baker SJ. PTEN function in normal and neoplastic growth. Cancer Lett 2006; 241: 184-196.
    • (2006) Cancer Lett , vol.241 , pp. 184-196
    • Chow, L.M.L.1    Baker, S.J.2
  • 16
    • 78449283888 scopus 로고    scopus 로고
    • Loss of PTEN expression by blocking nuclear translocation of EGR1 in gefitinibresistant lung cancer cells harboring epidermal growth factor receptor-activating mutations
    • Yamamoto C, Basaki Y, Kawahara A, et al. Loss of PTEN expression by blocking nuclear translocation of EGR1 in gefitinibresistant lung cancer cells harboring epidermal growth factor receptor-activating mutations. Cancer Res 2010; 70: 8715-8725.
    • (2010) Cancer Res , vol.70 , pp. 8715-8725
    • Yamamoto, C.1    Basaki, Y.2    Kawahara, A.3
  • 17
    • 44849093355 scopus 로고    scopus 로고
    • Restoration of PTEN expression alters the sensitivity of prostate cancer cells to EGFR inhibitors
    • Wu Z, Gioeli D, Conaway M, et al. Restoration of PTEN expression alters the sensitivity of prostate cancer cells to EGFR inhibitors. The Prostate 2008; 68: 935-944.
    • (2008) The Prostate , vol.68 , pp. 935-944
    • Wu, Z.1    Gioeli, D.2    Conaway, M.3
  • 18
    • 33846252977 scopus 로고    scopus 로고
    • PTEN and PIK3CA expression is associated with prolonged survival after gefitinib treatment in EGFR-mutated lung cancer patients
    • Endoh H, Yatabe Y, Kosaka T, et al. PTEN and PIK3CA expression is associated with prolonged survival after gefitinib treatment in EGFR-mutated lung cancer patients. J Thorac Oncol 2006; 1: 629-634.
    • (2006) J Thorac Oncol , vol.1 , pp. 629-634
    • Endoh, H.1    Yatabe, Y.2    Kosaka, T.3
  • 19
    • 74949110711 scopus 로고    scopus 로고
    • Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer
    • Jackman D, Pao W, Riely GJ, et al. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. J Clin Oncol 2009; 28: 357-360.
    • (2009) J Clin Oncol , vol.28 , pp. 357-360
    • Jackman, D.1    Pao, W.2    Riely, G.J.3
  • 20
    • 40049099220 scopus 로고    scopus 로고
    • The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
    • Yun CH, Mengwasser KE, Toms AV, et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci U S A 2008; 105: 2070-2075.
    • (2008) Proc Natl Acad Sci U S A , vol.105 , pp. 2070-2075
    • Yun, C.H.1    Mengwasser, K.E.2    Toms, A.V.3
  • 21
    • 33748074447 scopus 로고    scopus 로고
    • Presence of epidermal growth factor receptor gene T790M
    • Inukai M, Toyooka S, Ito S, et al. Presence of epidermal growth factor receptor gene T790M. Cancer Res 2006; 66: 7854-7858.
    • (2006) Cancer Res , vol.66 , pp. 7854-7858
    • Inukai, M.1    Toyooka, S.2    Ito, S.3
  • 22
    • 60549110433 scopus 로고    scopus 로고
    • MET increased gene copy number and primary resistance to gefitinib therapy in nonsmall-cell lung cancer patients
    • Cappuzzo F, Jänne PA, Skokan M, et al. MET increased gene copy number and primary resistance to gefitinib therapy in nonsmall- cell lung cancer patients. Ann Oncol 2009; 20: 298-304.
    • (2009) Ann Oncol , vol.20 , pp. 298-304
    • Cappuzzo, F.1    Jänne, P.A.2    Skokan, M.3
  • 23
    • 73649102105 scopus 로고    scopus 로고
    • Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC
    • Turke AB, Zejnullahu K, Wu YL, et al. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell 2010; 17: 77-88.
    • (2010) Cancer Cell , vol.17 , pp. 77-88
    • Turke, A.B.1    Zejnullahu, K.2    Wu, Y.L.3
  • 24
    • 14844366111 scopus 로고    scopus 로고
    • MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling
    • Engelman JA, Ja'nne PA, Mermel C, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Proc Natl Acad Sci U S A 2005; 102: 3788-3793.
    • (2005) Proc Natl Acad Sci U S A , vol.102 , pp. 3788-3793
    • Engelman, J.A.1    Ja'nne, P.A.2    Mermel, C.3
  • 25
    • 38049150665 scopus 로고    scopus 로고
    • MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib
    • Bean J, Brennan C, Shih JY, et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A. 2007; 104: 20932-20937.
    • (2007) Proc Natl Acad Sci U S A , vol.104 , pp. 20932-20937
    • Bean, J.1    Brennan, C.2    Shih, J.Y.3
  • 26
    • 62449250134 scopus 로고    scopus 로고
    • MET gene amplification or EGFR mutation activate MET in lung cancers untreated with EGFR tyrosine kinase inhibitors
    • Kubo T, Yamamoto H, Lockwood WW, et al. MET gene amplification or EGFR mutation activate MET in lung cancers untreated with EGFR tyrosine kinase inhibitors. Int J Cancer 2009; 124: 1778-1784.
    • (2009) Int J Cancer , vol.124 , pp. 1778-1784
    • Kubo, T.1    Yamamoto, H.2    Lockwood, W.W.3
  • 27
    • 33645958870 scopus 로고    scopus 로고
    • Role of ABCG2 as a biomarker for predicting resistance to CPT-11/SN-38 in lung cancer
    • Bessho Y, Oguri T, Achiwa H, et al. Role of ABCG2 as a biomarker for predicting resistance to CPT-11/SN-38 in lung cancer. Cancer Sci 2006; 97: 192-198.
    • (2006) Cancer Sci , vol.97 , pp. 192-198
    • Bessho, Y.1    Oguri, T.2    Achiwa, H.3
  • 28
    • 64949108700 scopus 로고    scopus 로고
    • Pharmacological interplay between breast cancer resistance protein and gefitinib in epiderimal growth factor receptor signaling
    • Katayama K, Shibata K, Mitsuhashi J, et al. Pharmacological interplay between breast cancer resistance protein and gefitinib in epiderimal growth factor receptor signaling. Anticancer Res 2009; 29: 1059-1065.
    • (2009) Anticancer Res , vol.29 , pp. 1059-1065
    • Katayama, K.1    Shibata, K.2    Mitsuhashi, J.3
  • 29
    • 2442638937 scopus 로고    scopus 로고
    • High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter
    • Ozvegy-Laczka C, Hegedus T, Varady G, et al. High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter. Mol Pharmacol 2004; 65: 1485-1495.
    • (2004) Mol Pharmacol , vol.65 , pp. 1485-1495
    • Ozvegy-Laczka, C.1    Hegedus, T.2    Varady, G.3
  • 30
    • 56449089812 scopus 로고    scopus 로고
    • Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations
    • Yano S, Wang W, Li Q, et al. Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. Cancer Res 2008; 68: 9479-9487.
    • (2008) Cancer Res , vol.68 , pp. 9479-9487
    • Yano, S.1    Wang, W.2    Li, Q.3
  • 31
    • 77958074157 scopus 로고    scopus 로고
    • TAK-701, a humanized monoclonal antibody to hepatocyte growth factor, reverses gefitinib resistance induced by tumor-derived HGF in non-small cell lung cancer with an EGFR mutation
    • Okamoto W, Okamoto I, Tanaka K, et al. TAK-701, a humanized monoclonal antibody to hepatocyte growth factor, reverses gefitinib resistance induced by tumor-derived HGF in non-small cell lung cancer with an EGFR mutation. Mol Cancer Ther 2010; 9: 2785-2792.
    • (2010) Mol Cancer Ther , vol.9 , pp. 2785-2792
    • Okamoto, W.1    Okamoto, I.2    Tanaka, K.3
  • 32
    • 66149158452 scopus 로고    scopus 로고
    • Perspectives in mammalian IGFBP-3 biology: Local vs. systemic action
    • C954-C976
    • Yamada PM, Lee KW. Perspectives in mammalian IGFBP-3 biology: Local vs. systemic action. Am J Physiol Cell Physiol 2009; 296: C954-C976.
    • (2009) Am J Physiol Cell Physiol , vol.296
    • Yamada, P.M.1    Lee, K.W.2
  • 33
    • 46749156706 scopus 로고    scopus 로고
    • Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins
    • Guix M, Faber AC, Wang SE, et al. Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. J Clin Invest 2008; 118: 2609-2619.
    • (2008) J Clin Invest , vol.118 , pp. 2609-2619
    • Guix, M.1    Faber, A.C.2    Wang, S.E.3
  • 34
    • 77952338791 scopus 로고    scopus 로고
    • ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation
    • Shi F, Telesco SE, Liu Y, et al. ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation. Proc Natl Acad Sci U S A 2010; 107 7692-7697.
    • (2010) Proc Natl Acad Sci U S A , vol.107 , pp. 7692-7697
    • Shi, F.1    Telesco, S.E.2    Liu, Y.3
  • 35
    • 77950216941 scopus 로고    scopus 로고
    • An ErbB3 antibody, MM-121, is active in cancers with ligand dependent activation
    • Schoeberl B, Faber AC, Li D, et al. An ErbB3 antibody, MM-121, is active in cancers with ligand dependent activation. Cancer Res 2010; 70: 2485-2494.
    • (2010) Cancer Res , vol.70 , pp. 2485-2494
    • Schoeberl, B.1    Faber, A.C.2    Li, D.3
  • 36
    • 80052437758 scopus 로고    scopus 로고
    • New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer
    • Oxnard GR, Arcila ME, Chmielecki J, et al. New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer. Clin Cancer Res 2011; 17: 5530-5537.
    • (2011) Clin Cancer Res , vol.17 , pp. 5530-5537
    • Oxnard, G.R.1    Arcila, M.E.2    Chmielecki, J.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.